OA
BMY.RT

Oak Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Oak Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31,295
Closed -$22K – 141
2020
Q4 		$22K Hold
31,295
– – ﹤0.01% 137
2020
Q3 		$70K Hold
31,295
– – ﹤0.01% 131
2020
Q2 		$112K Hold
31,295
– – 0.01% 134
2020
Q1 		$119K Hold
31,295
– – 0.01% 130
2019
Q4 		$94K Buy
+31,295
New +$81.4K 0.01% 149

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Oak Associates's BMY.RT Position: Q1 2021 in Review

Oak Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 31,295 shares — an estimated $22K sold.

Oak Associates first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $119K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Oak Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Oak Associates sold 31,295 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $22K.
  • Oak Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Oak Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $119K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Oak Associates's 13F filing for Q1 2021, filed 13 May 2021.